ALK-B Stock Analysis: ALK-Abelló | CO
Biotechnology | CO, Denmark | Market Cap: 43.985m DKK | 12M Return: -0.8% | DK0061802139 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.4M
EPS Trend: 97.7%
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ALK-Abelló A/S is a Denmark-based allergy solutions company founded in 1923 and headquartered in Horsholm. It develops and commercializes allergy immunotherapy treatments and related products across Europe, North America, and Asia.
The companys core business is allergen immunotherapy (AIT), which works by desensitizing patients to specific allergens through repeated, controlled exposure. It offers a broad portfolio covering tablets, sublingual drops, injections, and vaccines targeting grass, tree, ragweed, and Japanese cedar pollen, as well as house dust mites, peanuts, and tree nuts. Key brands include GRAZAX/GRASTEK, ACARIZAX, ODACTRA, ITULAZAX, RAGWITEK, and CEDARCURE.
Beyond AIT, ALK markets adrenaline nasal sprays and autoinjectors for emergency treatment of anaphylaxis, and is developing ALK 014, a biologic for food allergies. It also sells allergen extracts used in allergy diagnostics and operates klarify.me, a digital patient engagement platform. The company holds collaborations with Torii Pharmaceutical (for GRAZAX and CEDARCURE) and Dr. Reddys Laboratories (for Sensimune).
- US tablet franchise sales acceleration drives top-line growth
- ALK 014 peanut allergy biologic phase 3 data is key catalyst
- European pricing and reimbursement pressure compresses tablet margins
| Net Income: 1.36b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 18.20 > 1.0 |
| NWC/Revenue: 52.82% < 20% (prev 32.61%; Δ 20.21% < -1%) |
| CFO/TA 0.22 > 3% & CFO 2.16b > Net Income 1.36b |
| Net Debt (-1.05b) to EBITDA (2.20b): -0.48 < 3 |
| Current Ratio: 3.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (221.9m) vs 12m ago 1.24% < -2% |
| Gross Margin: 68.03% > 18% (prev 64.95%; Δ 3.08% > 0.5%) |
| Asset Turnover: 75.89% > 50% (prev 70.85%; Δ 5.04% > 0%) |
| Interest Coverage Ratio: 80.17 > 6 (EBIT TTM 1.84b / Interest Expense TTM 23.0m) |
| A: 0.37 (Total Current Assets 5.08b - Total Current Liabilities 1.47b) / Total Assets 9.72b |
| B: 0.71 (Retained Earnings 6.88b / Total Assets 9.72b) |
| C: 0.20 (EBIT TTM 1.84b / Avg Total Assets 9.00b) |
| D: 2.49 (Book Value of Equity 6.94b / Total Liabilities 2.78b) |
| Altman-Z'' = 8.74 = AAA |
| DSRI: 1.04 (Receivables 1.33b/1.09b, Revenue 6.83b/5.86b) |
| GMI: 0.95 (GM 64.95% / 68.03%) |
| AQI: 0.78 (AQ_t 0.24 / AQ_t-1 0.31) |
| SGI: 1.17 (Revenue 6.83b / 5.86b) |
| TATA: -0.08 (NI 1.36b - CFO 2.16b) / TA 9.72b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of September 27, 2026, the stock is trading at DKK 199.70 with a total of 198,183 shares traded. Over the past week, the price has changed by +0.60%, over one month by -4.36%, over three months by -21.99% and over the past year by -0.78%.
Current recommended Stop Loss: 194.50 (which is 2.6% or 1.2 ATR below the current price).
ALK-Abelló has no consensus analysts rating.
P/E Trailing = 32.5944
P/E Forward = 68.9655
P/S = 6.4494
P/B = 6.3604
P/EG = 9.8673
Revenue TTM = 6.83b DKK
EBIT TTM = 1.84b DKK
EBITDA TTM = 2.20b DKK
Long Term Debt = 143.0m DKK (from longTermDebt, last quarter)
Short Term Debt = 60.0m DKK (from shortTermDebt, last quarter)
Debt = 684.0m DKK (from shortLongTermDebtTotal, last quarter) + Leases 262.0m
Net Debt = -1.05b DKK (calculated: Debt 684.0m - CCE 1.74b)
Enterprise Value = 42.9b DKK (44.0b + Debt 684.0m - CCE 1.74b)
Interest Coverage Ratio = 80.17 (Ebit TTM 1.84b / Interest Expense TTM 23.0m)
EV/FCF = 23.18x (Enterprise Value 42.9b / FCF TTM 1.85b)
FCF Yield = 4.31% (FCF TTM 1.85b / Enterprise Value 42.9b)
FCF Margin = 27.12% (FCF TTM 1.85b / Revenue TTM 6.83b)
Net Margin = 19.86% (Net Income TTM 1.36b / Revenue TTM 6.83b)
Gross Margin = 68.03% ((Revenue TTM 6.83b - Cost of Revenue TTM 2.18b) / Revenue TTM)
Gross Margin QoQ = 66.57% (prev 69.34%)
Tobins Q-Ratio = 4.41 (Enterprise Value 42.9b / Total Assets 9.72b)
Interest Expense / Debt = 3.36% (Interest Expense 23.0m / Debt 684.0m)
Taxrate = 26.58% (491.0m / 1.85b)
NOPAT = 1.35b (EBIT 1.84b * (1 - 26.58%))
Current Ratio = 3.46 (Total Current Assets 5.08b / Total Current Liabilities 1.47b)
Debt / Equity = 0.10 (Debt 684.0m / totalStockholderEquity, last quarter 6.94b)
Debt / EBITDA = -0.48 (Net Debt -1.05b / EBITDA 2.20b)
Debt / FCF = -0.57 (Net Debt -1.05b / FCF TTM 1.85b)
Total Stockholder Equity = 6.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.07% (Net Income 1.36b / Total Assets 9.72b)
RoE = 20.76% (Net Income TTM 1.36b / Total Stockholder Equity 6.53b)
RoCE = 27.62% (EBIT 1.84b / Capital Employed (Equity 6.53b + L.T.Debt 143.0m))
RoIC = 16.97% (NOPAT 1.35b / Invested Capital 7.98b)
WACC = 6.98% (E(44.0b)/V(44.7b) * Re(7.05%) + D(684.0m)/V(44.7b) * Rd(3.36%) * (1-Tc(0.27)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 62.53 | Cagr: 2.28%
[DCF] Terminal Value 77.97% ; FCFF base≈1.14b ; Y1≈1.31b ; Y5≈1.92b
[DCF] Fair Price = 148.9 (EV 28.9b - Net Debt -1.05b = Equity 30.0b / Shares 201.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.72 | EPS CAGR: 51.95% | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.83 | Revenue CAGR: 14.39% | SUE: 1.00 | # QB: 2
EPS current Quarter (2026-09-30): EPS=1.70 | Chg30d=+0.00% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=6.51 | Chg30d=-1.63% | Revisions=+12% | GrowthEPS=+20.6% | GrowthRev=+15.9%
EPS next Year (2027-12-31): EPS=7.22 | Chg30d=-3.62% | Revisions=-38% | GrowthEPS=+11.0% | GrowthRev=+11.9%
[Analyst] Revisions Ratio: -7% (up=5, down=6)